Biologics in Asthma and COPD

In this episode of the UConn Internal Medicine Podcast Series, we discuss the evolving role of biologic therapies in asthma and COPD. We review how biologics target Type 2 inflammation, how to identify patients with severe asthma who may benefit from therapy, and how biomarkers such as blood eosinophils, FeNO, IgE, and allergic sensitization guide treatment selection.We also explore newly approved biologics for COPD, practical differences between available agents, expected benefits, steroid-sparing effects, safety considerations, pregnancy counseling, helminth screening, and real-world barriers such as cost and insurance approval.This episode is designed for internal medicine trainees and clinicians looking for a practical framework to understand when to consider biologics, how to choose the right agent, and what to monitor after starting therapy.Hosts:Dr. Hossam Albeyoumi Mohammed, and Dr. Simran Umra, Chief Medicine Residents, UConn.Dr. Alisa Pasichnik, and Dr. Caroline McCauley, 3rd year medicine residents, UConn.Guests:Dr. Ethan Bernstein, Associate Program Director of the Department of Pulmonary and Critical Care Medicine, UConn.Dr. Angela Quental, incoming Assistant Professor in the Department of Pulmonary and Critical care medicine, UConn.Edited by:Dr. Hossam Albeyoumi Mohammed, Chief Medicine Resident, UConn.Music:LoFi Girl by Snoozy Beats | Free Music Archive | Livense: CC BY.